ID

17784

Description

Glutamine in Treating Neuropathy Caused by Vincristine in Young Patients With Lymphoma, Leukemia, or Solid Tumors; ODM derived from: https://clinicaltrials.gov/show/NCT00365768

Link

https://clinicaltrials.gov/show/NCT00365768

Keywords

Versions (2)
  1. 10/2/16 10/2/16 -
  2. 10/3/16 10/3/16 -
Uploaded on

October 3, 2016

DOI

To request one please log in.

License

Creative Commons BY 4.0
Model comments :

You can comment on the data model here. Via the speech bubbles at the itemgroups and items you can add comments to those specificially.

Back to model comments
Itemgroup comments for :

Item comments for :

In order to download data models you must be logged in. Please log in or register for free.

Eligibility Kidney Cancer NCT00365768

English

Eligibility Kidney Cancer NCT00365768

1 forms  
Inclusion Criteria
Description

Inclusion Criteria

Alias
UMLS CUI
C1512693
patients between the age of 5 and 21 years old.
Description

Age

Data type

boolean

Alias
UMLS CUI [1]
C0001779
patients who demonstrate the ability to complete the assessment instruments at baseline.
Description

Assessment Complete Ability

Data type

boolean

Alias
UMLS CUI [1,1]
C1516048
UMLS CUI [1,2]
C0205197
UMLS CUI [1,3]
C0085732
patients who are diagnosed with leukemia or solid tumors and are expected to receive a cumulative dose of > or = to 6mg/m2 of vincristine, or > 6mg if individual vincristine doses are capped at 2mg according to primary cancer treatment protocol, over a 30-week period.
Description

leukemia | Solid tumour | Vincristine Cumulative Dose Expected | Vincristine individual dose

Data type

boolean

Alias
UMLS CUI [1]
C0023418
UMLS CUI [2]
C0280100
UMLS CUI [3,1]
C0042679
UMLS CUI [3,2]
C2986497
UMLS CUI [3,3]
C1517001
UMLS CUI [4,1]
C0042679
UMLS CUI [4,2]
C0677260
Exclusion Criteria
Description

Exclusion Criteria

Alias
UMLS CUI
C0680251
patients with primary cns tumors other than medulloblastoma or patients with cns metastasis.
Description

Primary malignant neoplasm of central nervous system | Medulloblastoma | CNS metastases

Data type

boolean

Alias
UMLS CUI [1]
C1455806
UMLS CUI [2]
C0025149
UMLS CUI [3]
C0686377
patients with recurrent disease.
Description

Recurrent disease

Data type

boolean

Alias
UMLS CUI [1]
C0277556
patients with grade ii, iii or iv neurological status by the nci ctc (ver. 3.0) on clinical exam.
Description

Neurological status | CTCAE grade finding | examination; clinical

Data type

boolean

Alias
UMLS CUI [1]
C0746866
UMLS CUI [2]
C3887242
UMLS CUI [3]
C1456356
patients who have already received > 8mg/m2 of vincristine, or > 8mg if individual vincristine doses are capped at 2mg according to primary cancer treatment protocol, during their course of therapy at time of consent.
Description

Vincristine Dose | Vincristine individual dose

Data type

boolean

Alias
UMLS CUI [1,1]
C0042679
UMLS CUI [1,2]
C0178602
UMLS CUI [2,1]
C0042679
UMLS CUI [2,2]
C0677260
patients with hepatic encephalopathy or hyperammonemia.
Description

Hepatic Encephalopathy | Hyperammonemia

Data type

boolean

Alias
UMLS CUI [1]
C0019151
UMLS CUI [2]
C0220994
patients with a focally abnormal neurologic exam.
Description

Neurological examination abnormal Focal

Data type

boolean

Alias
UMLS CUI [1,1]
C1112537
UMLS CUI [1,2]
C0205234
Back to the top of the page

Similar models

Eligibility Kidney Cancer NCT00365768

1 forms
Name
Type
Description | Question | Decode (Coded Value)
Data type
Alias
Item Group
C1512693 (UMLS CUI)
Age
Item
patients between the age of 5 and 21 years old.
boolean
C0001779 (UMLS CUI [1])
Assessment Complete Ability
Item
patients who demonstrate the ability to complete the assessment instruments at baseline.
boolean
C1516048 (UMLS CUI [1,1])
C0205197 (UMLS CUI [1,2])
C0085732 (UMLS CUI [1,3])
leukemia | Solid tumour | Vincristine Cumulative Dose Expected | Vincristine individual dose
Item
patients who are diagnosed with leukemia or solid tumors and are expected to receive a cumulative dose of > or = to 6mg/m2 of vincristine, or > 6mg if individual vincristine doses are capped at 2mg according to primary cancer treatment protocol, over a 30-week period.
boolean
C0023418 (UMLS CUI [1])
C0280100 (UMLS CUI [2])
C0042679 (UMLS CUI [3,1])
C2986497 (UMLS CUI [3,2])
C1517001 (UMLS CUI [3,3])
C0042679 (UMLS CUI [4,1])
C0677260 (UMLS CUI [4,2])
Item Group
C0680251 (UMLS CUI)
Primary malignant neoplasm of central nervous system | Medulloblastoma | CNS metastases
Item
patients with primary cns tumors other than medulloblastoma or patients with cns metastasis.
boolean
C1455806 (UMLS CUI [1])
C0025149 (UMLS CUI [2])
C0686377 (UMLS CUI [3])
Recurrent disease
Item
patients with recurrent disease.
boolean
C0277556 (UMLS CUI [1])
Neurological status | CTCAE grade finding | examination; clinical
Item
patients with grade ii, iii or iv neurological status by the nci ctc (ver. 3.0) on clinical exam.
boolean
C0746866 (UMLS CUI [1])
C3887242 (UMLS CUI [2])
C1456356 (UMLS CUI [3])
Vincristine Dose | Vincristine individual dose
Item
patients who have already received > 8mg/m2 of vincristine, or > 8mg if individual vincristine doses are capped at 2mg according to primary cancer treatment protocol, during their course of therapy at time of consent.
boolean
C0042679 (UMLS CUI [1,1])
C0178602 (UMLS CUI [1,2])
C0042679 (UMLS CUI [2,1])
C0677260 (UMLS CUI [2,2])
Hepatic Encephalopathy | Hyperammonemia
Item
patients with hepatic encephalopathy or hyperammonemia.
boolean
C0019151 (UMLS CUI [1])
C0220994 (UMLS CUI [2])
Neurological examination abnormal Focal
Item
patients with a focally abnormal neurologic exam.
boolean
C1112537 (UMLS CUI [1,1])
C0205234 (UMLS CUI [1,2])
Back to the top of the page 

Contact

Please use this form for feedback, questions and suggestions for improvements.

Fields marked with * are required.

Help

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial